Status:
COMPLETED
Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM Patients
Lead Sponsor:
Ain Shams University
Conditions:
GBM
Eligibility:
All Genders
18+ years
Brief Summary
The study aimed to investigate the role of promoter methylation of MGMT, NUPR1, NDRG2, and GLI1 genes in glioblastoma multiforme (GBM) patients. Tissue samples were collected from GBM patients and ind...
Detailed Description
Objectives. Elucidate the potential role of methylation levels of the MGMT, NUPR1, NDRG2, and GLI1 genes as epigenetic markers for GBM through measuring and comparing the methylation levels of four ge...
Eligibility Criteria
Inclusion
- Adult patients (age \> 18 years)
- Recent diagnosis of GBM
- Performance status of less than or equal to 2 on the Ester Clinical Oncology Group
- (ECOG) scale,1)
- Pathologically proven GBM
Exclusion
- Other types of cancer,
- HBV
- HCV
- Schistosomiasis
- HCC
- HIV
- Alcohol intake
- Thyroid dysfunction
- Inflammatory diseases
- Cerebrovascular disorders
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 9 2022
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT06538428
Start Date
September 1 2020
End Date
December 9 2022
Last Update
August 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain shams university hospital
Cairo, Egypt